A Bayesian model for identifying cancer subtypes from paired methylation profiles
- PMID: 36575828
- PMCID: PMC9851340
- DOI: 10.1093/bib/bbac568
A Bayesian model for identifying cancer subtypes from paired methylation profiles
Abstract
Aberrant DNA methylation is the most common molecular lesion that is crucial for the occurrence and development of cancer, but has thus far been underappreciated as a clinical tool for cancer classification, diagnosis or as a guide for therapeutic decisions. Partly, this has been due to a lack of proven algorithms that can use methylation data to stratify patients into clinically relevant risk groups and subtypes that are of prognostic importance. Here, we proposed a novel Bayesian model to capture the methylation signatures of different subtypes from paired normal and tumor methylation array data. Application of our model to synthetic and empirical data showed high clustering accuracy, and was able to identify the possible epigenetic cause of a cancer subtype.
Keywords: Bayesian method; cancer subtyping; clustering; paired methylation profiles.
© The Author(s) 2022. Published by Oxford University Press.
Figures
References
-
- Bailey P, Chang DK, Nones J, et al. . Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016;531(7592):47–52. - PubMed
-
- Felipe De Sousa EM, Wang X, Jansen M, et al. . Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013;19(5):614–8. - PubMed
-
- Yu F, Quan F, Xu J, et al. . Breast cancer prognosis signature: linking risk stratification to disease subtypes. Brief Bioinform 2019;20(6):2130–40. - PubMed
-
- Arnold M, Soerjomataram I, Ferlay J, et al. . Global incidence of oesophageal cancer by histological subtype in 2012. Gut 2015;64(3):381–7. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
